Ieq Capital LLC Takes Position in Ultragenyx Pharmaceutical Inc. $RARE

Ieq Capital LLC acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 106,026 shares of the biopharmaceutical company’s stock, valued at approximately $3,540,000. Ieq Capital LLC owned approximately 0.11% of Ultragenyx Pharmaceutical as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RARE. Versant Capital Management Inc increased its holdings in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $39,000. Harbor Investment Advisory LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $52,000. Parallel Advisors LLC boosted its position in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the period. Finally, Leonteq Securities AG grew its holdings in shares of Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on RARE. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, August 10th. Morgan Stanley upped their target price on Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $45.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, Guggenheim decreased their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.89.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $25.72 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $39.89. The firm’s 50-day simple moving average is $28.59 and its 200 day simple moving average is $24.98. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -4.40 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The company had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s revenue for the quarter was up 28.5% on a year-over-year basis. During the same period last year, the firm earned ($1.17) earnings per share. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.03 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares in the company, valued at $528,429.75. The trade was a 8.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 8,552 shares of company stock valued at $207,455. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.